Solaris Biolabs Secures £783.5k for BioCube Vertical Farming Technology

Solaris Biolabs Ltd produces clinically potent crops using modular BioCube controlled-environment agriculture units. Based in Norwich, the company targets high-value ingredient markets including sports nutrition, pharmaceuticals, and premium food. Its technology supports the production of ingredients for GLP-1 receptor agonists, a class of medications used for diabetes and weight management.

The company recently raised £783.5k in a new funding round. This investment places the post-money valuation of the business at approximately £5.7m. The capital injection follows the company's incorporation in 2024 and provides resources to further develop its vertical-farming systems.

Financial records show that Solaris Biolabs Ltd generated £228.7k in revenue during its most recent reporting period. The company achieved a profit of £107.1k and currently maintains a team of four employees. These figures reflect the early-stage operations of the Norwich-based startup as it scales its BioCube technology.

The BioCube system addresses the requirement for consistent, high-potency crop production within a controlled environment. By focusing on the pharmaceutical and sports nutrition sectors, Solaris Biolabs provides specialized raw materials that require precise growing conditions. The modular nature of the units allows for scalable production of these high-value ingredients.

Documentation for this funding round was filed in April, following an allotment of shares in January. The company continues to operate from its base in East Anglia, focusing on the intersection of agriculture and biotechnology.